| Schedule of Segment Reporting Information, by Segment |
The following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the Company’s reportable segment for the three months ended March 31, 2025 and March 31, 2024 (in thousands): | | | | | | | | | | | | | Three Months Ended
March 31, 2025 | | Three Months Ended
March 31, 2024 | | License and other revenue | $ | 15,000 | | | $ | — | | | Less: | | | | OX2R agonist program expenses | (20,093) | | | (4,652) | | LockBody program expenses | (3,418) | | | (4,170) | | | Discontinued R&D program expenses | (2,917) | | | (11,942) | | | Other R&D expenses: | | | | | Personnel expenses¹ | (6,302) | | | (5,599) | | | Research tax incentives | 4,259 | | | 7,860 | | | Other preclinical and clinical development expenses | (815) | | | (424) | | | General and administrative expenses¹ | (8,608) | | | (9,009) | | | Share-based compensation | (7,883) | | | (8,154) | | | Interest income | 7,890 | | | 2,591 | | | Interest expense | (2,877) | | | (2,529) | | | Other segment items² | 1,026 | | | (1,537) | | Income tax expense | (1,397) | | | (481) | | | Consolidated net loss | $ | (26,135) | | | $ | (38,046) | | | | | | | ¹ Excludes share-based compensation | | | | ² Other segment items includes non-operating income (expenses), net | | | |
|